Dermacyd Infantile (Lactic Acid)- Compatibility.
Phase 4
Completed
- Conditions
- Hygiene
- Interventions
- Drug: LACTIC ACID(ND)
- Registration Number
- NCT00881374
- Lead Sponsor
- Sanofi
- Brief Summary
Primary Objective:
To demonstrate the absence of irritation potential (primary dermic irritability and cumulated dermic irritability) and allergic potential (sensibilization) of the product Dermacyd Infantile.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Dermacyd Infantile (Lactic Acid) LACTIC ACID(ND) six weeks treatment
- Primary Outcome Measures
Name Time Method The absence of primary and accumulated dermic irritability and dermic sensitivity will be evaluated using International Contact Dermatitis Research Group (ICDRG) scale. During 6 weeks (i.e. treatment period)
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of lactic acid in reducing dermal irritation in infants?
How does lactic acid compare to other alpha hydroxy acids in infant skin compatibility studies?
Are there specific biomarkers associated with allergic reactions to lactic acid-based products in pediatrics?
What are the long-term safety profiles of lactic acid formulations in neonatal dermatological care?
What alternative emollients or moisturizers are used in infant hygiene alongside lactic acid for enhanced efficacy?
Trial Locations
- Locations (1)
Sanofi-Aventis Administrative Office
🇧🇷Sao Paulo, Brazil
Sanofi-Aventis Administrative Office🇧🇷Sao Paulo, Brazil